Overall, LAT1, ASCT2, and xCT are overexpressed through oncogenic, hypoxic, and epigenetic programs, support metabolic and redox demands, and predict poor outcomes, thereby establishing them as both biomarkers and therapeutic targets in NSCLC. This evidence concerns the gene SLC7A5 and non-small cell lung carcinoma.